PURE Bioscience (OTCMKTS:PURE) Stock Passes Above 200-Day Moving Average – Should You Sell?

Shares of PURE Bioscience (OTCMKTS:PURE) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.06 and traded as high as $0.0901. PURE Bioscience shares last traded at $0.0901, with a volume of 3,315 shares.

PURE Bioscience Price Performance

The firm has a market capitalization of $11.18 million, a PE ratio of -3.33 and a beta of 0.26. The stock has a 50-day moving average price of $0.06 and a 200 day moving average price of $0.06.

PURE Bioscience (OTCMKTS:PURE) last announced its earnings results on Monday, March 16th. The company reported ($0.01) earnings per share for the quarter. The firm had revenue of $0.44 million for the quarter.

About PURE Bioscience

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.